S.Korea's Hwajin Medical gets FDA sales approval for syringes

The company sells syringes to overseas markets including the US, Saudi Arabia, Vietnam and Mongolia

S.Korea's Hwajin Medical gets FDA sales approval for syringes
Jeong Min-nam 1
2023-02-17 14:08:32 peux@hankyung.com
Bio & Pharma

HLB Therapeutics Co. announced Thursday that Sofjec, a syringe produced by its subsidiary Hwajin Medical, has been approved for sale by the US Food and Drug Administration (FDA) on the 13th.

The items approved this time are injection needles and disposable syringes supplied by Hwajin.

Hwajin is currently selling syringes to overseas markets including the United States, Saudi Arabia, Vietnam and Mongolia, as well as in Korea.

According to Hwajin, Sofjec is in the form of filter paper attached to a needle, so it prevents the risk of harmful substances from entering the body.

Hwajin Medical is a medical device maker with a 100% stake held by HLB Therapeutics, a new drug development affiliate of the HLB Group.

Write to Jeong Min-nam at peux@hankyung.com
#HLB Therapeutics #Hwajin Medical #Sofjec #syringes #korea hlb therapeutics fda #hlb sofjec fda

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effective and safe in first phase 3 clinical trials (SEER-1).The research report, published by the International Journal of Molecular Sciences on Dec. 29,

HLB Therapeutics signs contract for COVID vaccine distribution rights

HLB Therapeutics signs contract for COVID vaccine distribution rights

Moderna vaccine at Incheon Int'l Airport (Courtesy of Yonhap) South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention Agency after being selected as a contractor to build and operate a storage and distri

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s (Hengrui Pharma) immuno-oncology drug camrelizumab was approved by the National Medical Products Administration (NMPA) as a first-lin

Retail investors test Celltrion, HLB shares as Korea’s GameStop

Retail investors test Celltrion, HLB shares as Korea’s GameStop

Celltrion Inc. and HLB Inc., two leading South Korean biopharmaceutical shares, shot up on Monday as the main bourse’s key index climbed back above the psychologically important 3,000 points.The usual suspect behind Celltrion’s rally was its announcement during the day that its bio
(* comment hide *}